We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Momenta Surges on Acquisition Deal With Johnson & Johnson
Read MoreHide Full Article
Shares of biotechnology company Momenta Pharmaceuticals, Inc. were up 69.17% after it announced that it will be acquired by pharma giant Johnson & Johnson (JNJ - Free Report) for $52.50 per share in an all-cash transaction. The total value of the transaction comes to $6.5 billion.
The transaction is expected to close in the second half of 2020. The agreement was unanimously approved by the boards of both Momenta and Johnson & Johnson.
The announcement was cheered by the investors as the price of $52.50 represents more than 70% premium to the closing price of $30.81 of Momenta. The transaction will give Janssen Pharmaceutical Companies of Johnson & Johnson full global rights to Momenta’s nipocalimab (M281), a clinically validated, potentially best-in-class anti-FcRn antibody.
While the acquisition will broaden Johnson & Johnson’s presence in immune-mediated diseases and provide it an opportunity to grow in the autoantibody-driven disease space, Momenta will get the much-needed cash influx and a strong partner to advance its portfolio of novel drug candidates for autoimmune and rare diseases.
Momenta’s novel therapeutics pipeline includes nipocalimab (M281), a fully human anti-neonatal Fc receptor (FcRn) aglycosylated immunoglobulin G (IgG1) monoclonal antibody (mAb) candidate.
Importantly, in June 2020, Momenta announced positive top-line data from an interim analysis of Vivacity-MG, the phase II study of nipocalimab in generalized myasthenia gravis (gMG). The results demonstrated that nipocalimab induced a rapid and durable response in the myasthenia gravis activities of daily living score (MG-ADL) at all doses and met the study’s primary efficacy endpoint, demonstrating a linear and highly statistically significant (p<0.0001) relationship between Immunoglobulin G (IgG) reduction and MG-ADL clinical benefit. The study is expected to be completed in the third quarter of 2020 and Momenta intends to present the full 16-week data in the fourth quarter of 2020. Additionally, Momenta has begun preparations to conduct an end of phase II meeting with the FDA before the end of 2020 and anticipates initiating a phase III study in the first quarter of 2021.
Additionally, Unity, Momenta’s global multi-center phase II study of nipocalimab in hemolytic disease of the fetus and newborn (HDFN), continues to enroll patients at sites where they can be safely accommodated.
While there are other promising candidates in the pipeline, nipocalimab’s positive phase II study results have grabbed the spotlight.
Momenta’s stock has rallied 164.1% in the year so far compared with the industry’s growth of 2.7%.
We believe the deal is positive for Momenta, given JNJ’s expertise in immunology and extensive capabilities, which gives the former a chance to turn over a new leaf with the successful development of the candidates.
The deal comes close on the heels of Sanofi’s (SNY - Free Report) announcement to acquire Principia Biopharma Inc. , a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases for $3.68 billion.
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Momenta Surges on Acquisition Deal With Johnson & Johnson
Shares of biotechnology company Momenta Pharmaceuticals, Inc. were up 69.17% after it announced that it will be acquired by pharma giant Johnson & Johnson (JNJ - Free Report) for $52.50 per share in an all-cash transaction.
The total value of the transaction comes to $6.5 billion.
The transaction is expected to close in the second half of 2020. The agreement was unanimously approved by the boards of both Momenta and Johnson & Johnson.
The announcement was cheered by the investors as the price of $52.50 represents more than 70% premium to the closing price of $30.81 of Momenta.
The transaction will give Janssen Pharmaceutical Companies of Johnson & Johnson full global rights to Momenta’s nipocalimab (M281), a clinically validated, potentially best-in-class anti-FcRn antibody.
While the acquisition will broaden Johnson & Johnson’s presence in immune-mediated diseases and provide it an opportunity to grow in the autoantibody-driven disease space, Momenta will get the much-needed cash influx and a strong partner to advance its portfolio of novel drug candidates for autoimmune and rare diseases.
Momenta’s novel therapeutics pipeline includes nipocalimab (M281), a fully human anti-neonatal Fc receptor (FcRn) aglycosylated immunoglobulin G (IgG1) monoclonal antibody (mAb) candidate.
Importantly, in June 2020, Momenta announced positive top-line data from an interim analysis of Vivacity-MG, the phase II study of nipocalimab in generalized myasthenia gravis (gMG). The results demonstrated that nipocalimab induced a rapid and durable response in the myasthenia gravis activities of daily living score (MG-ADL) at all doses and met the study’s primary efficacy endpoint, demonstrating a linear and highly statistically significant (p<0.0001) relationship between Immunoglobulin G (IgG) reduction and MG-ADL clinical benefit. The study is expected to be completed in the third quarter of 2020 and Momenta intends to present the full 16-week data in the fourth quarter of 2020. Additionally, Momenta has begun preparations to conduct an end of phase II meeting with the FDA before the end of 2020 and anticipates initiating a phase III study in the first quarter of 2021.
Additionally, Unity, Momenta’s global multi-center phase II study of nipocalimab in hemolytic disease of the fetus and newborn (HDFN), continues to enroll patients at sites where they can be safely accommodated.
While there are other promising candidates in the pipeline, nipocalimab’s positive phase II study results have grabbed the spotlight.
Momenta’s stock has rallied 164.1% in the year so far compared with the industry’s growth of 2.7%.
We believe the deal is positive for Momenta, given JNJ’s expertise in immunology and extensive capabilities, which gives the former a chance to turn over a new leaf with the successful development of the candidates.
The deal comes close on the heels of Sanofi’s (SNY - Free Report) announcement to acquire Principia Biopharma Inc. , a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases for $3.68 billion.
Momenta currently carries a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>